




FIG. 1




FIG. 2




FIG. 3

3/17




FIG. 4A




FIG. 4B





FIG. 5B




FIG. 6

6/17

FIG. 7





FIG. 8



7/17

FIG. 9






FIG. 10A



9/17


FIG. 10B



10/17

FIG. 11A

Anti-PD-L1 SOFUSA® 24h



11/17

FIG. 11B




FIG. 12A





FIG. 12B



14/17

FIG. 13

DAY	GROUP	ANIMAL NUMBER	SEX	TA OR CAV	DOSE			ANIMAL WEIGHT ^d (kg)	TARGET DOSE VOLUME ^a (mL)	
					LEVEL ^c	ROUTE	CONCENTRATION (mg/mL)			
PHASE I ^b										
1	1	1001	M	TA	7.755	L	51.7	2.745	0.15 (dose 1)	
					12.925				0.25 (dose 2)	
					12.925				0.25 (dose 3)	
					12.925				0.25 (dose 4)	
	2	2501	F		NA	NA	2.663	NA		
PHASE II										
1	3	3001	M	CAV	0	IV	0	2.557	2.0	
		3501	F					2.768	2.1	
	4	4001	M	TA	40	IV	51.7	2.865	2.2	
		4501	F					2.590	2.0	
	5	5001	M	CAV	0	L	0	2.694	2.1	
		5501	F					2.573	2.0	
	6	6001	M	TA	40	L	51.7	2.725	2.1	
		6501	F					2.758	2.1	
	8	3	3001	M	CAV	0	IV	0	2.688	2.1
			3501	F					2.722	2.1
4		4001	M	TA	40	IV	51.7	2.877	2.2	
		4501	F					2.726	2.1	
5		5001	M	CAV	0	L	0	2.753	2.1	
		5501	F					2.613	2.0	
6		6001	M	TA	40	L	51.7	2.933	2.3	
		6501	F					2.779	2.1	

IV = INTRAVENOUS; L = LYMPHATIC; NA = NOT APPLICABLE

F = FEMALE; M = MALE

TA = TEST ARTICLE; CAV = CONTROL ARTICLE/VEHICLE

^a DOSE VOLUMES ROUNDED TO NEAREST 0.1 mL SYRINGE INCREMENT^b ANIMAL 1001 RECEIVED FOUR DOSES WITH AN HOUR (± 5 MINUTES)

APART USING ONE DEVICE AT A TIME, ANIMAL 2501 WAS NOT DOSED

^c PHASE I DOSE LEVEL (mg/ANIMAL); PHASE II DOSE LEVEL (mg/kg/dose)^d ANIMAL BODY WEIGHT DATA WERE ACQUIRED ON THE DAY PRIOR TO DOSING

FIG. 14

ASSAY	ANALYZED SAMPLE COLLECTION DAYS	PARAMETERS MEASURED	RESIDUAL SAMPLE DISPOSITION
HEMATOLOGY	PHASE I: DAYS -8 AND 1 ^b	HEMATOCRIT, HEMOGLOBIN, MEAN CORPUSCULAR HEMOGLOBIN, MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION, MEAN CORPUSCULAR VOLUME, MEAN PLATELET VOLUME, PLATELETS, RED BLOOD CELLS, RED CELL DISTRIBUTION WIDTH, RETICULOCYTE ABSOLUTE COUNT, RETICULOCYTE PERCENT, WHITE BLOOD CELLS, AND DIFFERENTIAL LEUKOCYTE ABSOLUTE COUNT: BASOPHILS, EOSINOPHILS, LYMPHOCYTES, MONOCYTES, AND NEUTROPHILS	STORED AT 2 TO 8 °C, AND DISCARDED AFTER ANALYSIS
COAGULATION		ACTIVATED PARTIAL THROMBOPLASTIN TIME, FIBRINOGEN, AND PROTHROMBIN TIME	STORED AT -86 TO -60 °C, AND DISCARDED AFTER ANALYSIS
SERUM CHEMISTRY	PHASE II: DAYS -8, 1 ^c , 2, 3, 4, 7, 10, 15, AND 22	ALANINE AMINOTRANSFERASE, ALBUMIN, ALBUMIN/GLOBULIN RATIO, ALKALINE PHOSPHATASE, ASPARTATE AMINOTRANSFERASE, BLOOD UREA NITROGEN, CALCIUM, CHLORIDE, CREATINE KINASE, CREATININE, GAMMA GLUTAMYL TRANSFERASE, GLOBULIN, GLUCOSE, INORGANIC PHOSPHOROUS, POTASSIUM, SODIUM, TOTAL BILIRUBIN, TOTAL CHOLESTEROL, TOTAL PROTEIN, AND TRIGLYCERIDE	STORED AT -86 TO -60 °C ^a

^a RESIDUAL SAMPLES WERE DISCARDED PRIOR TO STUDY REPORT FINALIZATION
^b BLOOD SAMPLE FOR CLINICAL PATHOLOGY WAS COLLECTED WITH THE DOSE 4 TK SAMPLE
^c BLOOD SAMPLES FOR CLINICAL PATHOLOGY WAS COLLECTED WITH THE 2 HOURS POSTDOSE TK SAMPLE





FIG. 16

TIMEPOINT	PEMBROLIZUMAB DOSE (mg)	NUMBER OF DoseConnect FOR ADMINISTRATION OF PEMBROLIZUMAB	INFUSION DURATION
CYCLE 1 DAY 1	20 mg	1 DEVICE	2.0 HOURS
CYCLE 1 DAY 8	67 mg	2 DEVICES	3.0 HOURS
CYCLE 1 DAY 15	113 mg	4 DEVICES	2.5 HOURS
CYCLE 2 DAY 1 CYCLE 2 DAY 8 CYCLE 2 DAY 15 ONLY FOR PARTICIPANTS CONTINUING WITH Q1W DOSING AFTER CYCLE 2: CYCLE ≥3 DAY 1 CYCLE ≥3 DAY 8 CYCLE ≥3 DAY 15	67 mg	2 DEVICES	3.0 HOURS
ONLY FOR PARTICIPANTS CONTINUING WITH Q3W DOSING AFTER CYCLE 2: CYCLE ≥3 DAY 1	200 mg	4 DEVICES	4.5 HOURS